UNSPSC 51284305: Thiamphenicol aminoacetate hydrochloride

This classification denotes a protein synthesis inhibitor and antibiotic C14H18Cl2N2O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88VGC22BWE, chemically known as glycine, (2r,3r)-2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-(methylsulfonyl)phenyl)propyl ester, hydrochloride (1:1), but more generally known as thiamphenicol aminoacetate hydrochloride, which bears US NIH Compound Identifier 3039735.

UNSPSC 51284305 Thiamphenicol aminoacetate hydrochloride is a Commodity code that nominally names a specific pharmaceutical compound, but recent state and local opportunities tagged under this code show minimal relevance to that narrow product specification. The four most recent opportunities posted between January and June 2026 involve broader medical and pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, first-aid supplies for emergency response, and generic multi-source pharmaceuticals distributed through wholesalers. None of these solicitations reference thiamphenicol aminoacetate hydrochloride by name or chemical designation. The mismatch suggests either that state and local procurement systems are applying the code as a catch-all tag for pharmaceutical purchases outside their intended taxonomy classification, or that the code's scope in practice diverges significantly from its nominal substance name. Issuing bodies span county health departments, state health and human services agencies, municipal fire departments, and multi-state cooperative purchasing alliances, indicating that health-related pharmaceutical and medical supply procurement is distributed across jurisdictional levels.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon, with the largest and most complex solicitation originating from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration, which manages contracts across multiple states. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS seeking 1,900 units of naloxone and 800 drug deactivation systems annually (due July 26, 2023); the City of Tampa's ITB 26P00145 for medical and first-aid supplies totaling an estimated $700,000 with SLBE set-aside and a 5% bid discount (due March 13, 2026); the Texas Health and Human Services Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription procurement capabilities (due April 3, 2026); and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. Given the disconnect between the code's narrow chemical designation and the actual work being solicited, pursuit of opportunities under this code requires careful verification that individual opportunities genuinely match firm capabilities in pharmaceutical manufacturing or distribution rather than relying on UNSPSC tagging alone.